Yamada Masahito, Nozaki Ichiro, Hamaguchi Tsuyoshi, Noguchi-Shinohara Moeko, Kitamoto Tetsuyuki, Nakamura Yosikazu, Sato Takeshi, Mizusawa Hidehiro
Department of Neurology and Neurobiology of Aging, Kanazawa University Graduate School of Medical Science.
Rinsho Shinkeigaku. 2009 Nov;49(11):939-42. doi: 10.5692/clinicalneurol.49.939.
The Creutzfeldt-Jakob Disease (CJD) Surveillance Committee has identified 1,241 patients with prion diseases during 1999-2009, including 953 with sporadic CJD (sCJD) (76.8%), 207 with genetic prion diseases (16.7%), 78 with environmentally acquired prion diseases (6.3%), and 3 with unclassified CJD. Among atypical cases of sCJD, most common was MM2 type including the cortical and thalamic forms. The genetic cases included 84 with a PrP V180I mutation (40.6%), 37 with a P102L mutation (17.9%), 34 with a E200K mutation (16.4%), 32 with a M232R mutation (15.5%), 4 with a P105L mutation (1.9%), and so on. The environmentally acquired cases included 77 with dura mater graft-associated CJD (dCJD) and one with variant CJD (vCJD). Combined with the results by the previous surveillance systems, a total number of dCJD in Japan was 135. The vCJD patient had a history of short stay in the UK and presented with periodic electroencephalogram in the late stage. Although there was no evidence of association of surgical procedures or blood transfusion with sCJD, 4.5% of the sCJD patients underwent operations after the onset of sCJD, including neurosurgical for 0.8% and ophthalmic for 1.9%, requiring more attention on prion diseases to reduce the iatrogenic risk.
克雅氏病(CJD)监测委员会在1999年至2009年期间共确诊了1241例朊病毒病患者,其中包括953例散发性克雅氏病(sCJD)(76.8%)、207例遗传性朊病毒病(16.7%)、78例环境获得性朊病毒病(6.3%)以及3例未分类的克雅氏病。在sCJD的非典型病例中,最常见的是MM2型,包括皮质型和丘脑型。遗传性病例包括84例携带PrP V180I突变(40.6%)、37例携带P102L突变(17.9%)、34例携带E200K突变(16.4%)、32例携带M232R突变(15.5%)、4例携带P105L突变(1.9%)等等。环境获得性病例包括77例硬脑膜移植相关克雅氏病(dCJD)和1例变异型克雅氏病(vCJD)。结合以往监测系统的结果,日本dCJD的总数为135例。该vCJD患者有在英国短暂停留的病史,晚期出现周期性脑电图。尽管没有证据表明外科手术或输血与sCJD有关联,但4.5%的sCJD患者在发病后接受了手术,其中神经外科手术占0.8%,眼科手术占1.9%,需要更加关注朊病毒病以降低医源性风险。